Replies to post #200849 on Biotech Values

[DewDiligence]

I don't follow ILMN closely enough to give you an educated answer. Maybe someone else on the board will chime in.

[north40000]

Look at PACB's PRs in the last few months, from ~07/2015. A few days ago:

http://www.clintongazette.com/does-pacific-biosciences-of-california-nasdaqpacb-look-attractive-mkm-partners-starts-coverage/

"“Pacific Biosciences of California, Inc. is engaged in the development, manufacture and commercialization of its single molecule, real-time, or SMRT technology-an integrated platform for genetic analysis. The SMRT technology uses the natural processing power of enzymes, combined with specially designed reagents and detection systems, to record individual biochemical events as they occur. The Company’s technology platform comprises of the SMRT cells, Phospholinked nucleotides and the PacBio RS (an instrument that conducts, monitors and analyzes single molecule biochemical reactions in real time). Its product will find its application in both research institutions and commercial companies, including genome centers, government and academic institutions, genomic service providers, pharmaceutical companies and agriculture companies. Pacific Biosciences of California, Inc. is headquartered in Menlo Park, California.”

Heard somewhere questions about PACB's relative slowness to execution of its system in bringing to market.